{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MIBC", "query": { "condition": "MIBC" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MIBC&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-26T15:40:39.641Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03288545", "title": "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms" ], "interventions": [ { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 348, "start_date": "2017-10-11", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 83, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 75 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03288545" }, { "nct_id": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib Intravesical Delivery System", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-04-11", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316155" }, { "nct_id": "NCT03924856", "title": "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 907, "start_date": "2019-06-13", "completion_date": "2026-05-18", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 24, "location_summary": "La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03924856" }, { "nct_id": "NCT03636256", "title": "Evaluation of NanoDoce® in Participants With Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer", "Urothelial Carcinoma", "Urinary Bladder Neoplasm", "Urinary Bladder Cancer", "Urogenital Neoplasms", "Urologic Neoplasms", "Urologic Cancer", "Malignant Tumor of the Urinary Bladder", "Cancer of the Bladder" ], "interventions": [ { "name": "NanoDoce (direct injection)", "type": "DRUG" }, { "name": "NanoDoce (intravesical instillation) - Visit 2 Instillation", "type": "DRUG" }, { "name": "Institutional Standard of Care", "type": "OTHER" }, { "name": "NanoDoce (intravesical instillation) - Induction and Maintenance Instillations", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NanOlogy, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-04-02", "completion_date": "2021-11-02", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03636256" }, { "nct_id": "NCT04241185", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Conventional Radiotherapy (Bladder only)", "type": "RADIATION" }, { "name": "Conventional Radiotherapy (Bladder and pelvic nodes)", "type": "RADIATION" }, { "name": "Hypofractionated Radiotherapy (Bladder only)", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Mitomycin C (MMC)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo to Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2020-05-19", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 24, "location_summary": "Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Pikeville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04241185" }, { "nct_id": "NCT05833867", "title": "Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Localized Muscle Invasive Bladder Urothelial Carcinoma", "Muscle-Invasive Bladder Carcinoma" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" }, { "name": "Adaptive Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Shilpa Gupta, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-04-01", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05833867" }, { "nct_id": "NCT02203136", "title": "Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Tissue Biopsy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 16, "start_date": "2014-06-25", "completion_date": "2019-05-16", "has_results": false, "last_update_posted_date": "2019-05-22", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203136" }, { "nct_id": "NCT01556243", "title": "Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "whole breast irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "FEMALE", "summary": "40 Years and older · Female only" }, "enrollment_count": 270, "start_date": "2012-07", "completion_date": "2023-04-15", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 350, "location_summary": "Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" }, { "city": "Emeryville", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01556243" }, { "nct_id": "NCT02389764", "title": "Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "BIBF 1120", "type": "DRUG" }, { "name": "Phone Call", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-06-22", "completion_date": "2019-06-08", "has_results": true, "last_update_posted_date": "2019-07-17", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02389764" }, { "nct_id": "NCT07893509", "title": "Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NMIBC", "MIBC", "Muscle Invasive Bladder Cancer (MIBC)", "Non Muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "This is a non-interventional, observational, prospective study.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Bladder Cancer Advocacy Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1400, "start_date": "2027-03", "completion_date": "2032-05", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-26T15:40:39.641Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07893509" } ] }